The Reporting Sensitivities of Two Passive Surveillance Systems for Vaccine Adverse Events

Overview

Journal Am J Public Health

Specialty Public Health

Date 1995 Dec 1

PMID 7503351

Citations 44

Authors

S Rosenthal

R Chen

Affiliations

Soon will be listed here.

Abstract

To evaluate reporting sensitivities for vaccine adverse events, reporting rates were estimated by dividing the number of events reported to the Monitoring System for Adverse Events Following Immunization and the Vaccine Adverse Event Reporting System in a given period by the number of doses administered or distributed during the same period. Reporting sensitivity was calculated as the ratio of the rates at which events were reported to each passive surveillance system (numerator) and occurred in controlled studies (denominator). Reporting sensitivities were generally better in the public sector than in the private sector. The significant underreporting of known outcomes, together with the nonspecific nature of most adverse event reports, highlights the limitations of passive surveillance systems in assessing the incidence of vaccine adverse events.

Citing Articles

Data quality and timeliness analysis for post-vaccination adverse event cases reported through healthcare data exchange to FDA BEST pilot platform.

Deady M, Duncan R, Jones L, Sang A, Goodness B, Pandey A Front Public Health. 2024; 12:1379973.

PMID: 39040857 PMC: 11260708. DOI: 10.3389/fpubh.2024.1379973.

Active Vaccine Safety Surveillance: Global Trends and Challenges in China.

Liu Z, Meng R, Yang Y, Li K, Yin Z, Ren J Health Data Sci. 2024; 2021:9851067.

PMID: 38487501 PMC: 10880162. DOI: 10.34133/2021/9851067.

Otorhinolaryngologic complications after COVID-19 vaccination, vaccine adverse event reporting system (VAERS).

Shin J, Shim S, Lee J, Ryu H, Kim J Front Public Health. 2024; 11:1338862.

PMID: 38269374 PMC: 10807421. DOI: 10.3389/fpubh.2023.1338862.

Autoimmune disorders reported following COVID-19 vaccination: A disproportionality analysis using the WHO database.

Kim S, Bea S, Choe S, Choi N, Shin J Eur J Clin Pharmacol. 2024; 80(3):445-453.

PMID: 38212538 DOI: 10.1007/s00228-023-03618-w.

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study.

Winkelmann A, Metze C, Zettl U, Loebermann M Sci Rep. 2023; 13(1):14480.

PMID: 37660223 PMC: 10475060. DOI: 10.1038/s41598-023-41271-6.

References

Chen R, Haber P, Mullen J . Surveillance of the safety of simultaneous administration of vaccines. The Centers for Disease Control and Prevention experience. Ann N Y Acad Sci. 1995; 754:309-20. DOI: 10.1111/j.1749-6632.1995.tb44464.x. View

Chen R, Rastogi S, Mullen J, Hayes S, Cochi S, Donlon J . The Vaccine Adverse Event Reporting System (VAERS). Vaccine. 1994; 12(6):542-50. DOI: 10.1016/0264-410x(94)90315-8. View

Pollock T, Morris J . A 7-year survey of disorders attributed to vaccination in North West Thames region. Lancet. 1983; 1(8327):753-7. DOI: 10.1016/s0140-6736(83)92037-8. View

Stetler H, Orenstein W, Bart K, Brink E, Brennan J, Hinman A . History of convulsions and use of pertussis vaccine. J Pediatr. 1985; 107(2):175-9. DOI: 10.1016/s0022-3476(85)80120-7. View

Pollock T, Miller E, Mortimer J, Smith G . Post-vaccination symptoms following DTP and DT vaccination. Dev Biol Stand. 1985; 61:407-10. View

Sills J, Tanner L, Milstien J . Food and Drug Administration monitoring of adverse drug reactions. Am J Hosp Pharm. 1986; 43(11):2764-70. View

Walker A, Jick H, Perera D, Thompson R, Knauss T . Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health. 1987; 77(8):945-51. PMC: 1647245. DOI: 10.2105/ajph.77.8.945. View

Stetler H, Mullen J, Brennan J, Livengood J, Orenstein W, Hinman A . Monitoring system for adverse events following immunization. Vaccine. 1987; 5(3):169-74. DOI: 10.1016/0264-410x(87)90094-6. View

Deforest A, Long S, LISCHNER H, Girone J, Clark J, Srinivasan R . Simultaneous administration of measles-mumps-rubella vaccine with booster doses of diphtheria-tetanus-pertussis and poliovirus vaccines. Pediatrics. 1988; 81(2):237-46. View

10.

Cochi S, Edmonds L, Dyer K, Greaves W, Marks J, Rovira E . Congenital rubella syndrome in the United States, 1970-1985. On the verge of elimination. Am J Epidemiol. 1989; 129(2):349-61. DOI: 10.1093/oxfordjournals.aje.a115138. View

11.

Sutter R, Cochi S, Brink E, Sirotkin B . Assessment of vital statistics and surveillance data for monitoring tetanus mortality, United States, 1979-1984. Am J Epidemiol. 1990; 131(1):132-42. DOI: 10.1093/oxfordjournals.aje.a115466. View

12.

Scott H, Rosenbaum S, Waters Jr W, Green M, Andrews L, Faich G . Physician reporting of adverse drug reactions. Results of the Rhode Island Adverse Drug Reaction Reporting Project. JAMA. 1990; 263(13):1785-8. View

13.

Fletcher A . Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. J R Soc Med. 1991; 84(6):341-4. PMC: 1293280. DOI: 10.1177/014107689108400612. View

14.

Griffin M, Ray W, Mortimer E, Fenichel G, Schaffner W . Risk of seizures after measles-mumps-rubella immunization. Pediatrics. 1991; 88(5):881-5. View

15.

Sutter R, Cochi S . Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting. JAMA. 1992; 267(3):386-91. View

16.

Strebel P, Sutter R, Cochi S, Biellik R, Brink E, Kew O . Epidemiology of poliomyelitis in the United States one decade after the last reported case of indigenous wild virus-associated disease. Clin Infect Dis. 1992; 14(2):568-79. DOI: 10.1093/clinids/14.2.568. View

17.

Nieminen U, Peltola H, Syrjala M, Makipernaa A, Kekomaki R . Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr. 1993; 82(3):267-70. DOI: 10.1111/j.1651-2227.1993.tb12657.x. View

18.

Cody C, Baraff L, Cherry J, Marcy S, MANCLARK C . Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics. 1981; 68(5):650-60. View